I-BET151 (GSK1210151A)

目录号:S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A)是一种新型,选择性的BET抑制剂,作用于BRD2,无细胞试验中BRD3BRD4IC50分别为0.5 μM, 0.25 μM和0.79 μM。

规格 价格 库存 购买数量  
RMB 1382.25 现货
RMB 2231.18 现货
RMB 7130.63 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的2个实验数据:

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

    B. Western blot analysis of pERK and ERK in cells treated with JQ1 or I-BET151.

    Oncotarget, 2016, 7(3):2545-54. I-BET151 (GSK1210151A) purchased from Selleck.

产品安全说明书

Epigenetic Reader Domain抑制剂选择性比较

生物活性

产品描述 I-BET151 (GSK1210151A)是一种新型,选择性的BET抑制剂,作用于BRD2,无细胞试验中BRD3BRD4IC50分别为0.5 μM, 0.25 μM和0.79 μM。
特性 优化I-BET151,使其有效及选择性靶向作用于BET,同时增强体内药代动力学和终末半衰期,以使延长体内研究。
靶点
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
体外研究

I-BET151有效,选择性作用于多种不同蛋白类型,如COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, 离子通道,转运体。与I-BET762 (GSK525762A)类似, I-BET151 对BRD2, BRD3 和BRD4具有高的结合亲和力,Kd为0.02-0.1 μM,作用于人类外周血单核细胞(PBMC)和全血(WB)以及大鼠WB,显著抑制脂多糖刺激的IL-6细胞因子产生,IC50分别为0.16 μM, 1.26 μM, 和 1.26 μM。I-BET151(0.5 or 5 μM)作用于HL60核提取物,抑制BETs(BRD2, BRD3, BRD4, 和 BRD9)而非23种其他溴区蛋白结合到乙酰化的组蛋白肽。I-BET151有效作用于含不同 MLL融合的细胞系,如MV4;11, RS4;11, MOLM13, 和NOMO1 细胞, IC50为15-192 nM。一致的是,I-BET151完全消除MLL融合驱动的白血病(MOLM13)而非酪氨酸激酶激活(K562)驱动的白血病的菌落形成潜力。I-BET151也有效作用于液体培养和转化MLL-ENL或MLL-AF9的原代小鼠祖细胞的克隆形成实验。I-BET151作用于由不同的MLL融合(分别含MLL-AF9和MLL-AF4的MOLM13和MV4;11)而非K562细胞驱动的MLL融合细胞系,显著诱导细胞凋亡和G0/G1期停滞,可能是由于通过抑制BRD3/4,PAFc和SEC组分招募到转录起始位点(TSS),而抑制BCL-2,C-MYC和CDK6的转录。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 MUXjfZRwfG:6aXPpeJkh[XO|YYm= NXTINnJThjFyMDFOwG0> M1ni[2ROW09? NVLwXnhJUUN3ME2yOkBvVQ>? NXvENpM4OjF7NkSzOFA>
RS4;11 MoLIZ5l1d3SxeHnjbZR6KGG|c3H5 M2exN54yODBizszN MXzEUXNQ NX;sVZFbUUN3ME2xPVIhdk1? NFfRe3gzOTl4NEO0NC=>
MOLM13 MkjHZ5l1d3SxeHnjbZR6KGG|c3H5 M2LyWp4yODBizszN NUPyW5RjTE2VTx?= M1i3Z2lEPTB;MUKwJI5O MVqyNVk3PDN2MB?=
NOMO1 M4CwXIN6fG:2b4jpZ4l1gSCjc4PhfS=> MYn+NVAxKM7:TR?= Mo\2SG1UVw>? NVfaN4k{UUN3ME2xOUBvVQ>? NFSxe|IzOTl4NEO0NC=>
HEL M1vldIN6fG:2b4jpZ4l1gSCjc4PhfS=> NWC3TpI4hjFyMDFOwG0> Mn\zSG1UVw>? MmTYTWM2OD1zIN88US=> M2nKUVIyQTZ2M{Sw
K562 NXTrWYJw[3m2b4TvfIlkcXS7IHHzd4F6 M2T3dp4yODBizszN M3;xR2ROW09? MVjJR|UxRjFyMDFOwG0> MYGyNVk3PDN2MB?=
MEG01 MnjuZ5l1d3SxeHnjbZR6KGG|c3H5 Mn\PglExOCEQvF2= MoTzSG1UVw>? MmfvTWM2OD1{NTFOwG0> M1zwVlIyQTZ2M{Sw
HL60 M{CyWIN6fG:2b4jpZ4l1gSCjc4PhfS=> M4DEeJ4yODBizszN MlTRSG1UVw>? NVTnOHBFUUN3ME24PVAhdk1? NXvsdolVOjF7NkSzOFA>
MV4;11 MYDBdI9xfG:|aYOgZZN{[Xl? NYH2TFgyhjFyMDFOwG0> MnrQSG1UVw>? Mn3rbY5lfWOnczDhdI9xfG:|aYO= M3LqbFIyQTZ2M{Sw
MOLM13 NX\CWGNySXCxcITvd4l{KGG|c3H5 Mk\rglExOCEQvF2= MU\EUXNQ MmTabY5lfWOnczDhdI9xfG:|aYO= M1HYVFIyQTZ2M{Sw
MV4;11 MWfGeY5kfGmxbjDhd5NigQ>? M4XISWROW09? NFnUd4Jl\WO{ZXHz[ZMhfGinIILlZ5J2cXSvZX70JI9nKEKUREOvOEBidmRiaX3wZYlz\WRicnXjdpVqfG2nboSgc4YhS0SNOTDhcoQhWEGIMTD0c{B1cGVidILhcpNkemmydHnvcoFtKHO2YYL0JJNqfGV? NWfsN5ZrOjF7NkSzOFA>
PBMC M3m4SWZ2dmO2aX;uJIF{e2G7 M1XKTGROW09? MlfTbY5pcWKrdIOgTWwuPiC5aYToJJBKSzVyIH;mJFYvPw>? M1e1NlIzPDN5MUG1
A2 NYq0WVd6TnWwY4Tpc44h[XO|YYm= NF3tTmJ,OTBizszN M1fNNGROW09? NIj6N49z\WGldHn2ZZRmeyCuYYTlcpQhUEmYLUG= NG\QTngzOzJ3NUKxPC=>
A72 NFTCXXZHfW6ldHnvckBie3OjeR?= NIn0O|Z,OTBizszN MnzhSG1UVw>? MUDy[YFkfGm4YYTld{Bt[XSnboSgTGlXNTF? NVjvXZlpOjN{NUWyNVg>
BC1 M3\SS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYL+NUDPxE1? NEnjd4dFVVOR M2\TTmlEPTB;MkKwJI5O MkHpNlM4QTJ2NEi=
BC3 NWSxcIxwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVH+NUDPxE1? M3nvZWROW09? M2\TOWlEPTB;NE[wJI5O MnrnNlM4QTJ2NEi=
BCBL1 M3zzPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVz+NUDPxE1? NFjkbpJFVVOR NF3FW49KSzVyPUOzNEBvVQ>? NH7mT4UzOzd7MkS0PC=>
BJAB MkPNS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmfBglEh|ryP M3e4d2ROW09? NGDH[IVKSzVyPUm3NEBvVQ>? NEP5[4gzOzd7MkS0PC=>
Namalwa NXjlfXRVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEn3O2Z,OSEQvF2= NFXuOpdFVVOR NHjLbWtKSzVyPUm3NEBvVQ>? MnzqNlM4QTJ2NEi=
Jurkat MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVP+NUDPxE1? NYDNbHFWTE2VTx?= MVnJR|UxRTF{MkCgcm0> NEPVZmEzOzd7MkS0PC=>
MM1S Mmr5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWPKcFJOhjFizszN NIPKcGFFVVOR MX\JR|UxRTd4MDDuUS=> MY[yN|c6OjR2OB?=
U266 MojwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mm\rglEh|ryP MlzqSG1UVw>? M1jVe2lEPTB;OUWwJI5O MonVNlM4QTJ2NEi=
UM-PEL-1 NGe1TXVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFr6OIV,OSEQvF2= NHHtd3VFVVOR NIC3VHlKSzVyPUKxNEBvVQ>? MVuyN|c6OjR2OB?=
UM-PEL-3 NXL2TFZkT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NH3WVop,OSEQvF2= MWjEUXNQ MVXJR|UxRTF6MDDuUS=> MonoNlM4QTJ2NEi=
BC1 NXjBbIdpTnWwY4Tpc44h[XO|YYm= MYq1NFAhdk1? M2ToeGROW09? MmP6bY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dB?= MUeyN|c6OjR2OB?=
BC3 NYH0ToVbTnWwY4Tpc44h[XO|YYm= NXHiXVNIPTByIH7N M332PGROW09? MULpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2 NWTvcW0xOjN5OUK0OFg>
BC1 M1TkXmZ2dmO2aX;uJIF{e2G7 M3v2U|gxOCCwTR?= M1TyRWROW09? NVHP[m82emWmdXPld{BkNU27YzDwdo91\WmwIHzleoVtew>? NXPuU|RFOjN5OUK0OFg>
BC3 MXLGeY5kfGmxbjDhd5NigQ>? MX:4NFAhdk1? M4jBPGROW09? NYnCXlRTemWmdXPld{BkNU27YzDwdo91\WmwIHzleoVtew>? NFzaZ2IzOzd7MkS0PC=>
H929 NYHscGkzTnWwY4Tpc44h[XO|YYm= MU\+NUDPxE1? NHPtOZlFVVOR NFLrSWNqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 MXiyOFM{PTR7OR?=
KMS12PE MWnGeY5kfGmxbjDhd5NigQ>? M1;0Vp4yKM7:TR?= MY\EUXNQ M3z3XYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NUD6b|NwOjR|M{W0PVk>
KMS12BM MonTSpVv[3Srb36gZZN{[Xl? MljzglEh|ryP NUnBWoV3TE2VTx?= NXrvNXAycW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MWqyOFM{PTR7OR?=
KMS18 M4LKTGZ2dmO2aX;uJIF{e2G7 NHvvbIF,OSEQvF2= M{[5cGROW09? MojzbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MWmyOFM{PTR7OR?=
KMS11 MXTGeY5kfGmxbjDhd5NigQ>? NVzXSI5ChjFizszN NXnzU4dCTE2VTx?= MkTPbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MXGyOFM{PTR7OR?=
RPMI8226 MmDCSpVv[3Srb36gZZN{[Xl? NHrLc|J,OSEQvF2= NWrDcllRTE2VTx?= M{PWRolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= M1fBVlI1OzN3NEm5
H929 NHvFdG5CeG:ydH;zbZMh[XO|YYm= MnvuglEh|ryP NWS5UWRZTE2VTx?= NYH5ZpZwcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXeyOFM{PTR7OR?=
KMS12PE MXjBdI9xfG:|aYOgZZN{[Xl? MWr+NUDPxE1? Mor0SG1UVw>? NGjvVmJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NEDCXIMzPDN|NUS5PS=>
KMS12BM MXnBdI9xfG:|aYOgZZN{[Xl? M2fKNJ4yKM7:TR?= MonnSG1UVw>? MUHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M2LMOlI1OzN3NEm5
KMS18 M1mwR2Fxd3C2b4Ppd{Bie3OjeR?= MVP+NUDPxE1? MmLRSG1UVw>? MVHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NGnnSI4zPDN|NUS5PS=>
KMS11 NFe3T4hCeG:ydH;zbZMh[XO|YYm= NXrldZBJhjFizszN MVjEUXNQ NW\5UHVrcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NYXEPZRlOjR|M{W0PVk>
RPMI8226 NHXqdIFCeG:ydH;zbZMh[XO|YYm= MUT+NUDPxE1? M1XubWROW09? Mln5bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NESxO|AzPDN|NUS5PS=>
U87MG NHG2NohHfW6ldHnvckBie3OjeR?= MlfmglExKM7:TR?= M3:wPGROW09? NWq2ZYxsemWmdXPld{BWQDePRzDj[YxtfWyjcjDBWHAhf2m2aDDJR|UxKG:oIEGuNFUh|ryP M1i4W|I1PDl4M{ix
A172 NGfxXoVHfW6ldHnvckBie3OjeR?= NYXKSoZPhjFyIN88US=> MkPoSG1UVw>? NY\VZ41KemWmdXPld{Bk\WyudXzhdkBCXFBid3n0bEBKSzVyIH;mJFEvOjhizszN NEnGd|UzPDR7NkO4NS=>
SW1783 MV7GeY5kfGmxbjDhd5NigQ>? NX64Tm1NhjFyIN88US=> NE\LbWdFVVOR Mn:1doVlfWOnczDj[YxtfWyjcjDBWHAhf2m2aDDJR|UxKG:oIEKuOlgh|ryP MXiyOFQ6PjN6MR?=
U87MG MYXGeY5kfGmxbjDhd5NigQ>? M1KzfZ4yOCEQvF2= NIDQdYhFVVOR M2qzO4lv[3KnYYPld{Bxem:yb4L0bY9vKG:oIHPlcIx{KGmwIITo[UBIOS:VIITyZY5{cXSrb36= NWC5VGR7OjR2OU[zPFE>
RAW267.4 NYnv[pJ2TnWwY4Tpc44h[XO|YYm= M4Tz[lEh|ryP NGnWUYJFVVOR MYry[YR2[2W|IFnMMVYheHKxZIXjeIlwdiCrbnT1Z4VlKGK7IFzQVy=> NUXxTIxmOjR6NUmwNFg>
RAW267.4 NHPqWndHfW6ldHnvckBie3OjeR?= NV7pPIxlOSEQvF2= MnTUSG1UVw>? M{S4WpJm\HWlZYOgeIhmKGG|c3;jbYF1cW:wIHLleJdm\W5iQmLEOEBidmRiYXPleJlt[XSnZDDwOlU> NHW1NlEzPDh3OUCwPC=>
Me007 M1\vOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIDwSmx,OTByIN88US=> MmH5SG1UVw>? MUfpcohq[mm2czD0bIUh\3Kxd4To M2PTUlI1QTB4MUO3
SK-Mel-28 NGjmT4ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NITrTll,OTByIN88US=> MojVSG1UVw>? MWXpcohq[mm2czD0bIUh\3Kxd4To M1q0VVI1QTB4MUO3
Mel-RMU NFWzXoVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NU\FO|UzhjFyMDFOwG0> M2PNR2ROW09? NXm3NlBbcW6qaXLpeJMhfGinIHfyc5d1cA>? M1;nOlI1QTB4MUO3
Mel-JD Mnn2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVX+NVAxKM7:TR?= MVTEUXNQ NGXFbZBqdmirYnn0d{B1cGViZ4Lve5Rp NYfjZ|NiOjR7ME[xN|c>
Mel-RM MUXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Moe3glExOCEQvF2= NGG5[VNFVVOR NWHnc|VkcW6qaXLpeJMhfGinIHfyc5d1cA>? MnrDNlQ6ODZzM{e=
Me007 NYTve28xSXCxcITvd4l{KGG|c3H5 NWTIcWhohjFyMDFOwG0> NFTPUXZFVVOR NHe0OIZqdmS3Y3XzJIFxd3C2b4Ppdy=> Mn;sNlQ6ODZzM{e=
SK-Mel-28 NGnrUI5CeG:ydH;zbZMh[XO|YYm= M3y0UZ4yODBizszN MX;EUXNQ NVvSVWdMcW6mdXPld{BieG:ydH;zbZM> NXfs[W9sOjR7ME[xN|c>
Mel-RMU Moj6RZBweHSxc3nzJIF{e2G7 MXj+NVAxKM7:TR?= MXTEUXNQ NV:1VoJDcW6mdXPld{BieG:ydH;zbZM> MYeyOFkxPjF|Nx?=
Mel-JD MkHmRZBweHSxc3nzJIF{e2G7 MWD+NVAxKM7:TR?= M17SbGROW09? MYPpcoR2[2W|IHHwc5B1d3Orcx?= NIXhU4YzPDlyNkGzOy=>
Mel-RM MonORZBweHSxc3nzJIF{e2G7 MX;+NVAxKM7:TR?= NYfNSWVwTE2VTx?= NF;mbHFqdmS3Y3XzJIFxd3C2b4Ppdy=> MUGyOFkxPjF|Nx?=
Me007 MmPQSpVv[3Srb36gZZN{[Xl? NHTVPYQyOCEQvF2= M2fJNWROW09? MXXpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> NFjEOFAzPDlyNkGzOy=>
SK-Mel-28 NVrGNVU3TnWwY4Tpc44h[XO|YYm= NXnEU3JiOTBizszN M1jKTGROW09? M37B[Ilv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? MlzyNlQ6ODZzM{e=
Mel-RMU MnO3SpVv[3Srb36gZZN{[Xl? MlizNVAh|ryP NUfpZ2FETE2VTx?= MV;pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> MoT4NlQ6ODZzM{e=
Mel-JD MlHrSpVv[3Srb36gZZN{[Xl? NVHlcFBHOTBizszN NXH4d4VkTE2VTx?= MlXObY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy MUKyOFkxPjF|Nx?=
Mel-RM MVLGeY5kfGmxbjDhd5NigQ>? M3v0e|ExKM7:TR?= M4DWcmROW09? MVPpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> NYi0dpRnOjR7ME[xN|c>
Me007 NF\XOmhHfW6ldHnvckBie3OjeR?= NUm0NI5NOTBizszN MVLEUXNQ NWfJVG42fXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> MUWyOFkxPjF|Nx?=
SK-Mel-28 NGT4ZplHfW6ldHnvckBie3OjeR?= M4[4b|ExKM7:TR?= M37mNGROW09? NUi2bJNWfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> NHH1XJQzPDlyNkGzOy=>
Mel-RMU MYXGeY5kfGmxbjDhd5NigQ>? M3POcFExKM7:TR?= MoHXSG1UVw>? MXH1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| MmfKNlQ6ODZzM{e=
Mel-JD Mnf6SpVv[3Srb36gZZN{[Xl? NXnDfYxZOTBizszN NX;m[oF6TE2VTx?= NEDBOXl2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz M4DL[lI1QTB4MUO3
Mel-RM MnnBSpVv[3Srb36gZZN{[Xl? MlqzNVAh|ryP MVXEUXNQ MlvIeZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= M{[4b|I1QTB4MUO3

... Click to View More Cell Line Experimental Data

体内研究 I-BET151每天按30 mg/kg剂量处理小鼠,显著抑制鼠类MLL-AF9和人类MLL-AF4白血病肿瘤生长,显著延长寿命。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

荧光各向异性(FP)的配体位移检测:

所有组分溶解在50 mM HEPES pH 7.4, 150 mM NaCl和 0.5 mM CHAPS组成的Buffer中,BRD 2/3/4终浓度为75 nM,荧光配体为5 nM。在Greiner 384孔黑色的低量微孔板中,使用Micro Multidrop 将10 μL反应混合物加入到含100 nL各种浓度I-BET151或DMSO空白对照(1%最终)的孔中,并在黑暗中室温下平衡60分钟。使用 Envision (lex=485 nm,lEM=530 nm;Dichroic=505 nM)读取荧光各向异性。
细胞实验:

[1]

+ 展开
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 和 K562
  • Concentrations: 溶于DMSO, 终浓度为~100 μM
  • Incubation Time: 24,或72小时
  • Method:

    使用多种不同浓度I-BET151在384孔或96孔板中处理细胞24或72小时。细胞生长抑制实验中,实验板每孔中加入与细胞培养基同等体积的CellTiter-Glo试剂,震荡约2分钟,然后在Analyst GT 或EnVision酶标仪上读取化学发光信号。细胞增殖实验中,每孔加入CellTiter-Aqueous One,然后实验板在37°C下温育4小时。在SpectraMax Gemini酶标仪上490 nm处读取吸光度。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 静脉注射MV4;11细胞的NOD-SCID小鼠,静脉注射MLL-AF9细胞的C57BL/6小鼠
  • Formulation: 溶于含5% (v/v) DMSO和10% (w/v) Kleptose HPB的生理盐水中
  • Dosages: ~30 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 415.44
化学式

C23H21N5O3

CAS号 1300031-49-5
稳定性 powder
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Related Antibodies

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: 购买I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A)供应商 | 采购I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A)价格 | I-BET151 (GSK1210151A)生产 | 订购I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID